Amgen’s rival to AbbVie’s Humira to launch in 2023
September 28, 2017 at 11:08 AM EDT
AbbVie shares surged to a record high on the news, that Amgen’s biosimilar to AbbVie’s blockbuster Humira won’t launch in the U.S. for over 5 years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.